|View printer-friendly version|
|Array BioPharma Appoints Dr. Jonathan Kay to Its Scientific Advisory Board for Inflammation Therapy|
New Member Brings Broad Rheumatology Expertise
BOULDER, Colo.--(BUSINESS WIRE)--May 8, 2007--Array BioPharma Inc. (NASDAQ: ARRY) today announced the appointment of Jonathan Kay, M.D., to its Scientific Advisory Board. Dr. Kay will work with the Array team to facilitate the development of its inflammation portfolio.
"Dr. Kay's vast experience with novel therapies in the clinic, as well as his strong research interest to improve clinical practice in rheumatology, will be a valuable scientific addition to Array," said Kevin Koch, Ph.D., President and Chief Scientific Officer, Array BioPharma. "As a leader in the field of rheumatology he will contribute valuable knowledge and expertise as we move our inflammation programs forward in clinical development."
"It is a great opportunity to participate in developing Array's promising drug pipeline," said Dr. Kay. "I look forward to helping to guide the development of Array's breakthrough treatments for inflammation as a member of the Scientific Advisory Board."
Background - Jonathan Kay, M.D.
Dr. Kay is the Director of Clinical Trials in the MGH Rheumatology Unit and an Associate Clinical Professor of Medicine at Harvard. Dr. Kay has been a principal investigator on over 30 clinical trials of novel therapies for rheumatoid arthritis, gout and osteoarthritis. He is the author of more than 50 publications and book chapters and is internationally recognized as a leader improving the clinical practice of rheumatology.
Dr. Kay received his undergraduate degree from Harvard University and his medical degree from the University of California School of Medicine in San Francisco. He completed training in Internal Medicine at the Hospital of the University of Pennsylvania and fellowships in Rheumatology and Immunology at the Brigham and Women's Hospital and Harvard Medical School in Boston.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life-threatening and debilitating diseases. Our proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2006, our quarterly report on Form 10-Q for the quarter ended March 31, 2007, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet objectives tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of May 8, 2007. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
CONTACT: Array BioPharma Inc.